The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Prasterone (Intrarosa®) has been rejected for use in the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms. The manufacturer did not make a submission to the SMC and as such it cannot be recommend.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« CKS Updates - November 2019||Drug Safety Update - December 2019 »|